Table 4.

Previous studies of 8-OHdG and/or 8-OHG in PD CSF.

	Kikuchi et al., 2002	Abe et al., 2003	Gmitterová et al., 2009	Isobe et al., 2010
Study subjects	31 PD, 16 MSA, 29 controls	24 PD, 15 controls	27 PD without dementia, 21 PD with dementia, 18 LBD, 18 AD, 13 non-demented neurological controls	20 PD, 20 controls
Variable measured	“8-OHdG/8-OHG” ( = 8-OHdG + 8-OHG)	8-OHG	8-OHdG	8-OHdG
Method	ELISA (in-house)	HPLC	ELISA (IBL Transatlantic)	HPLC
Results	PD: 2.85 ± 2.43 ng/mL; MSA: 4.24 ± 3.53 ng/mL;Controls: 1.46 ± 0.83 ng/mL	PD: 288 ± 129 pM(86.1 ± 38.6 pg/mL);Controls: 97 ± 32 pM (29.0 ± 11.5 pg/mL)	PD: 1.0 ± 0.45 ng/mL; PD with dementia: 0.90 ± 0.38 ng/mL; LBD: 0.83 ± 0.25 ng/mL;AD: 0.89 + 0.47 ng/mL;Controls: 0.71 ± 0.29 ng/mL	PD: 5.8 ± 4.5 pg/mL;Controls: 1.8 ± 0.6 pg/mL
Conclusions	PD > Controls (p < 0.0005)	PD > Controls (p < 0.001)	PD without dementia > non-demented neurological Controls (p = 0.03)	PD > Controls (p < 0.0001)

Two studies measured 8-OHdG, one measured 8-OHG, and one measured both variables. The methods for these measurements included in-house ELISA, commercial ELISA, and HPLC. Results are shown as means and SDs. The range of measurements for 8-OHdG concentrations varies widely between the studies. (PD, Parkinson’s disease; MSA, multiple system atrophy; LBD, Lewy body dementia; AD, Alzheimer’s disease; HPLC, high performance liquid chromatography).